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Abstract 
 
Introduction:  Community acquired pneumonia (CAP) is a major health problem in 
elderly persons and is associated with high morbidity and mortality.  
Areas covered:  This article reviews the most recent publications relative to CAP in the 
elderly population, with a focus on epidemiology, prognostic factors, microbial 
etiology, therapy and prevention. The data discussed in this review were mainly 
obtained from a non-systematic review using Medline, and references from relevant 
articles. 
Expert Commentary: CAP can occur at any age, but its incidence and risk of death are 
linked to increasing age. Age-related changes in the immune system make this 
population more vulnerable to CAP. Mortality in hospitalized patients with CAP ranges 
from 10% to 12%. However, in the case of elderly patients, several studies have 
reported mortality rates of up to 25%. Pneumococcal and influenza vaccination 
comprise one of the most important preventive approaches for CAP in the elderly. 
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1. - INTRODUCTION   
Community-acquired pneumonia (CAP) is a serious health problem associated with 
high morbidity and mortality in all age groups worldwide[1]. In a recently published 
article on the incidence of CAP in a UK region, where 17, 316 cases of CAP were 
analyzed, the study reported that the incidence of CAP increased from 4.2%/year 
between 1998 and 2008 to 8.8%/year between 2009 and 2014[2]. In 2013, The Global 
Burden of Disease Study found that lower respiratory tract Infections (LRTI) were the 
second cause of death, based on data from 188 countries around the world [3]. In 
Europe, the mortality rates for CAP vary widely from country to country, ranging from 
<1% to 48% [4].  
CAP can occur at any age, but its incidence and risk of death are linked to increasing 
age [5-7]. Older age is an important risk factor for pneumonia and is associated with 
elevated morbidity and mortality due to the physiological changes associated with 
aging and a greater presence of chronic disease. The incidence of CAP in patients over 
the age of 65 years accounts for 25 to 35 cases per 1000 inhabitants/year [6-8]. A 
study by Cillóniz et al on microbial etiology of CAP by comorbidity found that age does 
not significantly affect pathogen patterns; however, the main factors associated with 
mortality were neurologic diseases, the presence of a potential MDR pathogen, and 
very advanced age (>85 years)  [5]. 
There is a strong association between advanced age and the decline in the integrity of 
physical barriers, protection against invading pathogens, and age-related changes in 
the immune system, which make this population vulnerable to CAP, and clinicians 
should pay close attention to this entity due to increased life expectancy in the coming 
years. 
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2. - Age-Related Changes in the Immune System 
The human lung has an effective and complex defense against respiratory infections. 
Impairment of mucociliary clearance (that prevents attachment of bacteria to the 
epithelium), impairment of alveolar defense, ineffective cough, and swallowing 
disorders are altered lung mechanisms of defense in elderly patients[11]. 
Immunological changes that occur with age involving decreased efficiency of the 
adaptive and innate immune systems are called “Immunosenescence”. 
Immunosenescence is known to be responsible for the increased susceptibility of the 
host to infectious diseases and limited response to vaccines[9]. Consequences of 
immunosenescence in patients with CAP include the risk of misdiagnosis in this 
population because some specific symptoms of infection such as cough, fever, and 
leukocyte count do not reflect the real state of elderly patients with pneumonia[10]. 
Figures 1 and 2 show age-related changes to the adaptive and innate immune system 
in elderly persons. 
3. - Epidemiology  
The global population is currently aging rapidly. According to 2015 data from the 
United Nations World Population Prospects, the world population reached 7.3 billion 
in mid-2015. This data reported that, in 2015, there were 901 million people aged 60 
or over, comprising 12% of the global population. The population aged 60 or over was 
growing at a rate of 3.26% per year.  By 2050, in all major areas of the world except 
Africa, it is expected that nearly a quarter or more of the population will be aged 60 
years or over. The number of older persons in the world is projected to reach 1.4 
billion by 2030 and 2.1 billion by 2050, and could rise to 3.2 billion by 2100[12]. 
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The study by Jain et al[13] found an increased incidence of hospitalized CAP with 
increasing age. The annual incidence of pneumonia was 24.8 cases per 10,000 adults, 
with the highest rates among adults between 65 and 79 years of age (63.0 cases per 
10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults). A 
Germany study by Ewig et al[14] on the impact of age and comorbidities on the 
etiology of hospitalized CAP patients, including 2,049  patients, reported that age does 
not influence the microbial cause itself, but the mortality rate increased with age (65-
74 years, 6.9%; 75-84 years, 8.9%; > 85 years, 17.1%; P < .001).  
The economic cost related to CAP remains high. A recently published Dutch study that 
included 195,372 CAP cases reported that the median costs of CAP case were 
dependent on age and type of care, with costs ranging from €344 (€482) per episode 
for 0-9 year olds treated as outpatients, to €10,284 (€16,374) per episode for 50-64 
year olds admitted to the ICU. In this study the majority of CAP episodes (64%) and 
costs (76%) occurred among patients aged over 50 years [15]. 
Mortality in hospitalized patients with CAP ranges from 10% to 12%. However, in the 
case of elderly patients, several studies reported that mortality rates can reach up to 
25%[[6;16;17]. A recently published study examining the impact of age and 
comorbidities on mortality in a cohort of 6,205 patients with CAP suggests that 
patients aged ≥ 80 years, instead of ≥ 65 years, should be considered a risk factor for 
poor outcome[18]. 
4. - Interactions Between Age and Comorbidities 
Elderly persons suffer from a variety of chronic diseases; these comorbidities will affect 
the integrity of host resistance to infections with the consequence that they are 
exposed to increased risk of morbidity and mortality. The immune dysfunction 
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associated with aging is responsible for the reduced response to infection and 
increased pathological disorders in the elderly population. 
In 80% of the CAP cases in the study by Cilloniz et al[5] on the impact of age and 
comorbidities on the etiology of pneumonia, at least one comorbidity (chronic 
respiratory disease, diabetes mellitus, chronic cardiovascular disease, neurological 
disease, chronic liver disease, and chronic renal disease) was present at the following 
rates by age group: 65-74 yrs, 77.6%; 75-84 yrs, 80.6%; and ≥ 85 yrs, 80.8%. The most 
frequent comorbidity in all age groups in this study was chronic pulmonary disease 
(54.1%). COPD was the most frequent respiratory comorbidity decreasing in frequency 
with age[5]. 
Recently, a study by Kofteridis et al[19] of diabetes mellitus 2 in elderly CAP patients 
showed that elderly patients with diabetes mellitus, despite initial lower CURB65 
scores, required longer hospitalization and had worse outcomes compared with 
patients without diabetes mellitus 2. 
There are several risk factors for pneumonia in elderly patients. Jackson et al[20] 
identified cardiopulmonary comorbidities, weight loss, and the presence of functional 
or cognitive impairments as independent risk factors for pneumonia.  
5. - Microbial Etiology 
Microbiological diagnosis in CAP constantly decreased with each age group, as 
reported by Cilloniz et al[5] in a study that analyzed microbial etiology by age group in 
a cohort of 2,149 CAP patients. Microbiological diagnosis was as follows: 65–74 years, 
43.7%; 75–84 years, 40.7%; and ≥85 years, 31.4% (p<0.001).  
In several worldwide clinical studies on the microbial etiology of CAP in elderly 
patients, including nursing-home patients, Streptococcus pneumoniae (pneumococcus) 
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remains the most frequent pathogen in CAP[5;21;22]. A Spanish study [5] on the 
impact of age and comorbidities on the etiology of CAP in a population of 2,149 
patients, excluding nursing home cases and which categorized the population in 3 age 
groups (65 to 74 years; 75 to 84 years; > 85 years) reported that age does not influence 
microbial etiology by itself. Streptococcus pneumoniae was the most frequent 
pathogen reported in all age groups (40.7%, 39.4%, and 48.9%, respectively), followed 
by mixed etiology (16.0%, 13.1%, and 10.6%), atypical pathogens (16.0%, 13.1%, and 
9.9%), and respiratory viruses (8.4%, 14.6%, and 11.3%). In patients where at least one 
comorbidity was present, Haemophilus influenzae was the most common pathogen, 
and multidrug-resistant pathogens (MDR) were common in patients with one or more 
comorbidities. However, a recently published study by Jain et al[13] in 2,480 
hospitalized patients with CAP reported that respiratory viruses (human rhinovirus and 
influenza virus) are the most frequent pathogens (15%) in this population, followed by 
pneumonia due to S pneumoniae (5%). The study concluded that the incidence 
increased with age for each pathogen. 
An interesting study carried out in the United States [23] on the distribution of 
pneumococcal serotypes in patients over 50 years of age by using urine antigen 
detection (UAD) assay capable of detecting 13-valent pneumococcal conjugate vaccine 
(PCV13) associated serotypes reported that PCV13 associated serotypes were 
identified in 11% of pneumococcal CAP cases and 7-valent pneumococcal conjugate 
vaccine (PCV7) serotypes were identified in 25% of cases. The study concluded that 
pneumococcal serotypes causing non-invasive pneumonia in adults may differ 
significantly from those causing invasive disease.  
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The most frequent respiratory viruses in the elderly population are influenza virus and 
respiratory syncytial virus, which cause high morbidity and mortality. There are many 
reports of epidemic outbreaks, especially in nursing home patients. It has also been 
reported that respiratory viruses may not only cause viral pneumonia but are also 
associated with bacterial infection (polymicrobial CAP); the most frequent bacterial 
pathogens associated with respiratory viruses are S pneumoniae, S aureus, and H 
influenzae [24-26]. 
Several studies have reported a low rate of MDR in the elderly population and the 
most frequently reported pathogens were methicillin–resistant Staphylococcus aureus 
(MRSA) and gram-negative bacteria (Haemophilus influenzae, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, etc). Elderly patients are a population susceptible 
to admission to a nursing home residence, and differences regarding etiology have 
been reported from different parts of the world. In Europe, two reports on nursing 
homes showed similar etiology to that reported in community-acquired pneumonia 
[21;27].   
In elderly patients, clinicians should carefully consider the presence of specific risk 
factors associated with MDR pathogens, such as prior antibiotic therapy [28;29], 
chronic pulmonary disease[5;29], admission to a nursing home [22;30], and  prior 
hospitalization.  
6. - Clinical Presentation and Diagnosis of CAP 
Clinical presentation of pneumonia in elderly patients may be different from that of 
the general adult population; in general, the more common symptoms associated with 
pneumonia in elderly persons are falls and altered mental status, fatigue, lethargy, 
delirium, anorexia, tachypnea, tachycardia, and, less commonly, pleuritic pain, cough, 
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fever, and leukocytosis[10;31].  Since most elderly patients present with one or more 
comorbidities, pneumonia sometimes presents as an exacerbation or decompensation 
of these comorbidities (Figure 3). A chest x-ray is required to confirm pneumonia. 
However, in this special population, radiographic findings are not conclusive or are 
confusing in approximately 30% of cases[1;32]. A study by Haga et al[33] on the 
diagnostic utility of computed tomography compared to chest x-ray in the diagnosis 
and evaluation of pneumonia severity in elderly patients showed that approximately 
10% of CT-determined pneumonic infiltration was overlooked by chest x-ray based 
diagnosis. The authors demonstrated that CT was superior to chest x-ray for 
diagnosing and evaluating the severity of CAP in elderly patients.   
More recently, the study by Ticinesi et al[34], which compared the accuracy of lung 
ultrasound and standard chest x-ray for the diagnosis of pneumonia in 169 older 
patients, showed that diagnosis accuracy for pneumonia was significantly higher in 
lung ultrasound compared with standard chest x-ray, with better sensitivity and 
negative predictive value.  
Some diseases and syndromes have clinical signs and symptoms that can mimic 
pneumonia in elderly patients. In adults over 65 years old, the incidence of 
tuberculosis is higher than in other age groups with the exception of the HIV-infected 
population[35]. Clinicians should be taken into account the fact that, in nursing home 
patients, the incidence of tuberculosis is approximately 3 times higher than in patients 
living in the community. We should also remember that the elderly population is a 
reservoir of tuberculosis and should suspect this entity, which may be misdiagnosed as 
bacterial pneumonia[10;35]. 
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Worldwide data show that the percentage of people living with HIV at an advanced 
age (50 years and above) has increase in the last decade. In elderly patients, HIV 
infection is often discovered by opportunistic pulmonary infections that mimic 
pneumonia[36].  
Congestive heart failure in elderly patients presenting at the emergency department 
with respiratory symptoms and suspicion of pneumonia is a frequent entity, as chronic 
cardiovascular disease  is a frequent comorbidity in this population[5]. In these cases, 
the use of biomarkers such as procalcitonin measurement will help identify patients 
with bacterial infection and guide antibiotic therapy. Elderly patients with congestive 
heart failure and elevated procalcitonin levels suggest bacterial infection[37;38].  
7. - Prognostic Factors (Figure 4) 
A recently published study by Akirov et al[39] on the prognostic value of glucose levels 
in elderly patients with pneumonia, in a cohort of 2,164 elderly patients, showed that, 
in elderly non-diabetic patients hospitalized for pneumonia, moderate and markedly 
elevated blood glucose levels on admission were associated with increased short-term 
and long-term mortality. 
Neupane et al[40], in a study of predictive factors of in-hospital mortality and re-
hospitalization in 717 enrolled older CAP patients, reported that chronic comorbidities 
are the main predictor of death and re-hospitalization in older patients with CAP, while 
vitamin E supplementation was protective. 
A recently published study by Luna et al[18] on the impact of age and comorbidities on 
the mortality of different age groups with CAP found that the presence of 
comorbidities is associated with poor outcome in CAP patients. The study also 
  
IERX-1240037-Blind Manuscript- Page 12 of 34   
reported that age ≥80 years is a factor for increased mortality when patients presented 
less than 1 comorbidity. 
Several scores exist to predict 30-day mortality and admission to the ICU. In these 
scores, age is an important factor.  
The scores most widely used to predict mortality are PSI [41] and CURB65[42]; the 
former was developed by Fine et al and includes 21 variables, among which age has 
considerable weight. In the validation cohort, the people in higher categories (IV, V) 
were elderly (median, 75 years old) and were not assigned to this category due to their 
age alone. In the PSI, nursing home residence increases the risk of 30-day mortality. 
The CURB65 is a score that includes 5 variables, one of which is age 65 years or older. 
These useful scores are easy to use and include variables that are widely available. In a 
recent study, Luna et al[18] observed that age did not add to mortality in CAP until 80 
years old if only 1 comorbidity or no comorbidities were present; furthermore, there 
are significant differences in the simplified CRB-65 between patients under 65 years 
old, those aged 65 to 79 years, and those over 80 years.  
Chen et al[43] evaluated the performance of these two scores in a young, elderly and 
very old population, and found the worst performance of the scores, mainly in PSI, in 
the elderly and very old population. This may be due an overestimated weight of age. 
The author proposed a modified score excluding age in this population.  
Among the scores for predicting admission to the ICU, need for vasoactive drugs, or 
need for mechanical ventilation, the most commonly used are the SMART-COP[44] and 
the score proposed by ATS/IDSA guidelines[1]. Age is not present in the ATS/IDSA 
guidelines and in the SMART-COP, the cutoff for age was 50 years. 
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Physicians should pay particular attention to specific factors of this population that 
may predict a poor outcome, such as previous bed confinement, abnormal mental 
status, absence of chills, or nutritional status[45;46].  
To predict treatment failure, a composite outcome associated with mortality, several 
risk factors have been described by Menendez et al[47]. Independent risk factors 
include liver disease, PSI score, leukopenia, multilobar pneumonia, pleural effusion, 
and radiological signs of cavitation. Independent factors associated with a lower risk of 
treatment failure were influenza vaccination, initial treatment with fluoroquinolones, 
and chronic obstructive pulmonary disease (COPD).  Age is not present among these 
variables but elderly patients are more likely to present these factors, leading to a 
higher PSI score, as described above. 
8.- Treatment 
The cornerstone in the treatment of pneumonia is antibiotic treatment. Empirical 
treatment may vary in accordance with different guidelines; however, the main 
guidelines recommend empirical treatment for severe pneumonia that covers S 
pneumoniae and atypical germs such as L pneumophila, M pneumoniae and Chlamydia 
species[1;48]. The most widely used empirical treatment is β-lactam with inhibitor of 
beta lactamase or 3rd generation cephalosporins plus a macrolide, or a respiratory 
fluoroquinolone (Figure 5). The benefit of combination therapy with macrolides over 
other antibiotic treatment is the subject of debate. According to retrospective 
analysesand non-interventional studies, macrolide combination therapy reduces 
mortality, mainly in patients with severe pneumonia[49-51]. Macrolides have an 
immunomodulatory effect in the lung and their benefits in the treatment of pulmonary 
disease go beyond the antimicrobial effect [52], and they have proven benefits in non-
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infectious pulmonary disease such as cystic fibrosis [53], COPD[54], and 
bronchiectasis[55]. In recent studies, therapy with β-lactams alone show non-
inferiority in 90-day mortality [56] compared to a combination of β-lactams plus 
macrolides or fluoroquinolones; however, these studies were carried out in patients 
not admitted to the ICU. In another prospective study, therapy with β-lactams alone 
did not show non-inferiority in the proportion of patients who reached clinical stability 
by day 7[57]. 
In 2005, the ATS/IDSA introduced a new concept, “health care associated pneumonia”, 
a heterogeneous population with a risk of higher mortality and germs with multidrug 
resistance [1]. This population included patients residing in nursing homes. In two 
European cohorts, we observed that etiology in nursing home acquired pneumonia, 
did not differ from that observed in community acquired pneumonia not requiring 
broad-spectrum antibiotics[21;27]. To calculate the risk of multidrug-resistant germs, 
we developed a score to detect PES (P aeruginosa, extended-spectrum β-lactamase 
[ESBL]) Enterobacteriaceae, and MRSA pathogens in CAP patients aged between 40 
and 65 years, where male sex scored 1 point, age >65 years, prior antibiotic treatment, 
chronic respiratory disease, and consciousness impairment scored 2 points, and 
chronic renal failure scored 3 points. One point is reduced when patients present fever 
in the emergency room. In this score, patients with 5 points or higher had a risk of PES 
pathogen. Belonging to the elderly population was included as a risk factor in this 
score[29]. 
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9. - Adjunctive Treatments 
The mortality associated with CAP remains high despite appropriate antibiotic 
treatment [58] and for this reason, adjunctive therapies are becoming a major subject 
of study. A retrospective non-interventional study described a benefit for statins, 
angiotensin-converting enzyme, and angiotensin II receptor blocker in different 
outcomes in patients with CAP[59]. These drugs are commonly used by elderly patients 
with cardiovascular disease. A meta-analysis found evidence that elderly patients 
treated with angiotensin-converting enzyme and, to a lesser extent, angiotensin II 
receptor blocker, had lower rates of hospitalization for CAP; further prospective 
studies should be performed to evaluate the benefits of these drugs[60]. In the case of 
statins, recent prospective studies evaluating statins in CAP found no evidence to 
suggest that statin use before and during hospitalization improved outcomes in CAP 
[61;62]. 
In severe CAP, high levels of inflammatory cytokines can be harmful and can cause 
pulmonary dysfunction associated with adverse outcomes. Corticosteroids are the 
most widely used anti-inflammatory drugs and have been shown to be effective at 
reducing treatment failure in patients with severe pneumonia and higher inflammatory 
response[63], and reducing the time to clinical stability by 1.4 days, length of stay by 1 
day, and time on intravenous antibiotics by 1 day [64], according to two recent 
randomized controlled trials. The benefits of corticosteroids in CAP were also observed 
in two recent meta-analyses, where a benefit was found regarding the risk of ARDS, 
need for mechanical ventilation, and reduced length of stay; disagreement persists 
regarding mortality. Corticosteroids did not increase adverse effects[65;66].     
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10. - Outcomes  
In-hospital mortality or 30-day mortality in hospitalized elderly patients with CAP 
ranges from 8% to 17% [5;14;67]. Advanced age is known to be associated with high 
risk of long-term mortality. Mortality at 6 months was reported to be 19% and 
mortality at 1 year was 41%[67;68].  
A study by Mortensen et al[69] analyzed 1555 CAP patients and assessed long-term 
mortality; the study reported that comorbid conditions (reflected by the Charlson 
comorbidity score), age, and nursing home residence were the strongest predictors of 
long-term mortality in CAP. Similarly, a study by Johnstone et al[70] on long-term 
morbidity and mortality reported that long-term morbidity and mortality are high 
following hospitalization for pneumonia and are strongly correlated with initial PSI 
class. 
A systematic review by Prescott et al[71]  on diagnosis of early and late readmission 
after hospitalization for CAP reported that early readmission (30 days) was more 
frequent in the elderly population (≥65 years) than  in the general adult population. 
11. - Prevention 
In elderly persons, immunosenescence is the main cause of insufficient protection 
following vaccination. The weak and low antibody response in elderly people is the 
principal problem. International guidelines [1;72] recommend specific measures to 
prevent pneumonia. The most important of these is the use of pneumococcal vaccines 
(polysaccharide and conjugated) and influenza vaccines in all older adults and for 
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younger persons with medical conditions that place them at a high risk of pneumonia 
morbidity and mortality. 
11.1 ACIP Recommendations 2015 for PCV13 and PPV23 in Adults [73;74]  
• Pneumococcal vaccine in naïve persons ≥ 65 years: naïve persons should 
receive a single dose of PCV13 first, followed by a dose of PPV23 ≥ 1 year later. 
• Prior vaccination with PPV23 at age ≥ 65 years: adults aged ≥65 years who 
have previously received ≥1 doses of PPV23 should also receive a dose of 
PCV13 if they have not yet received it. A dose of PCV13 should be given ≥ 1 year 
after receipt of the most recent PPV23 dose. In the case of patients who need 
repeating PPV23, the period between received PCV13 and the new dose of 
PPV23 should be ≥ 1 year, and 5 years after the most recent dose of PPV23. 
• ACIP recommendations for immunocompromised patients remain 
unchanged[75]. 
• The recommendations for routine PCV13 use among adults aged ≥65 years will 
be re-evaluated in 2018 and revised as needed. 
12. - Future Directions 
 
CAP in the elderly is an important health problem worldwide, as the global population 
is currently aging rapidly. In future clinical practice, combined specialist teams will be 
required for the management of elderly patients with pneumonia (pulmonary 
specialist, infectious diseases and geriatric specialists) in order to improve the 
management of patients. More clinical research is needed in order to provide more 
complete information to help with the management of pneumonia in this specific 
population. Research into rehabilitation of elderly patients after CAP episodes will 
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prevent physical dysfunction. Furthermore, future studies are needed to identify 
several indices for predicting overall mortality in different patient categories. More 
research on the use of corticosteroids in elderly patients with severe pneumonia is 
needed. It is also necessary to identify immunological biomarkers that help in the early 
detection of infection, the level of immune competence and mortality risk. National 
and International guidelines should be implemented based on current knowledge of 
pneumonia in the elderly in order to disseminate these research data worldwide. 
 
13. - Conclusion 
 
Community-acquired pneumonia in the elderly person is associated with high health 
costs, a high rate of readmission, and high mortality. Because the clinical presentation 
of pneumonia in elderly persons may be different from younger adults, clinicians 
should suspect pneumonia in older persons who have an atypical presentation in order 
to avoid complications associated with delayed treatment.  
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14. - Expert Commentary 
Because the global population is currently aging rapidly, the incidence of pneumonia in 
the elderly population is increasing. Pneumonia in the elderly is more likely to be 
severe, as a large proportion of patients suffer from comorbidities that complicate 
pneumonia presentation. 
In several worldwide clinical studies on the microbial etiology of CAP in elderly 
patients, including nursing-home patients, Streptococcus pneumoniae remains the 
most frequent pathogen in CAP. In elderly patients, clinicians should carefully consider 
the presence of specific risk factors associated with MDR pathogens, such as prior 
antibiotic therapy, chronic pulmonary disease, consciousness impairment, chronic 
renal failure, and prior hospitalization.  
In general, the more common symptoms associated with pneumonia in elderly persons 
are falls and altered mental status, fatigue, lethargy, delirium, anorexia, tachypnea, 
tachycardia, and, less commonly, pleuritic pain, cough, fever, and leukocytosis. Since 
most elderly patients present with one or more comorbidities, pneumonia sometimes 
presents as an exacerbation or decompensation of these comorbidities. 
The scores most widely used to predict mortality are PSI and CURB65. These scores 
perform worse in the elderly population due to the excess weight of age in the scores. 
Different cutoffs may improve the accuracy of severity scores in this population.  
Antimicrobial therapy for elderly patients is the same as for the general population; 
however, clinicians must take into account the presence of risk factors for 
multiresistant pathogens. Patients receiving combination therapy with macrolides may 
have a better outcome. A retrospective study demonstrated the safety of macrolide 
use in the elderly population in terms of cardiovascular adverse events.    
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Therapy with corticosteroids has been shown to be effective at reducing treatment 
failure in patients with severe pneumonia and higher inflammatory response, reducing 
time to clinical stability and length of stay. 
Some studies described a benefit of statins, angiotensin-converting enzyme, and 
angiotensin II receptor blocker in different outcomes in patients with CAP, further 
prospective studies should evaluated the use of these drugs in CAP. 
In-hospital mortality or 30-day mortality in hospitalized elderly patients with CAP 
ranges from 8% to 17%. Also advanced age is associated with high risk of long-term 
mortality. Early and late readmission after hospitalization for CAP is frequent in elderly 
patients. 
Vaccination is one of the most important preventive approaches for CAP in the elderly.  
15. - Five-Year view 
Development of new rapid microbiological tests will reduce the time to etiological 
diagnosis and help with prompt adequate antimicrobial therapy, thereby reducing the 
use of broad-spectrum antibiotics. 
New or modified severity scores are necessary to improve the clinical management of 
CAP in elderly patients. 
Further studies should evaluate the efficacy of adjunctive therapy with statins, 
angiotensin-converting enzyme, and angiotensin II receptor blocker in CAP in the 
elderly.  
Surveillance of etiological pathogens may improve vaccination policy in the elderly 
population.  
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16. - Key Issues 
• Community–acquired pneumonia (CAP) remains an important infection and 
cause for hospitalization in the elderly population.  
• Incidences of pneumonia increase with age and are associated with a high 
health cost. 
• The clinical presentation of pneumonia in the elderly differs from the general 
population and is a major challenge for clinicians. 
• Streptococcus pneumoniae is the main pathogen reported in this population.  
However, we should be cautious with patients with risk factors for 
multiresistant pathogens.  
• Pneumococcal and influenza vaccination comprise one of the most important 
preventive approaches for CAP in the elderly.  
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Figure 1. Changes in the adaptive immune system:  
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Figure 2. Changes in the innate immune system:  
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Figure 3. Common and less common signs and symptoms associated with CAP in elderly  
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Figure 5. Empirical therapy for CAP in elderly patient  
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*Treat previously healthy patients with low risk of drug-resistant pneumococci with a macrolide (azithromycin, 
clarithromycin, or erythromycin) or doxycycline.  
*Treat patients with a high risk of drug-resistant pneumococci with a fluoroquinolone or β-lactam plus 
macrolide. 
*Patients with comorbidities, use of immunosuppressing drugs, use of antimicrobials within the previous 3 
months, or other risks of DRSP infection: treat with respiratory fluoroquinolone (moxifloxacin or levofloxacin 
[750mg]). β-lactam plus a macrolide (high-dose amoxicillin [e.g., 1 g, three times daily] or amoxicillin-
clavulanate [2 g, twice daily] is preferred; alternatives include ceftriaxone, cefpodoxime, and cefuroxime 
[500mg, twice daily]; doxycycline is an alternative to the macrolide). 
* In regions with a high rate (>25%) of infection with high-level (MIC, ≥16mg/mL) macrolide-resistant 
Streptococcus pneumoniae: consider the use of alternatives to the agents listed above for any patient, including 
those without comorbidities. 
 
Hospitalized 
patients, non- ICU 
* β-lactam (preferred cefotaxime, ceftriaxone, and ampicillin) plus macrolide, alternative respiratory 
fluoroquinolone 
ICU patients  * β-lactam (preferred cefotaxime, ceftriaxone, and ampicillin) plus macrolide, alternative β-lactam (preferred 
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cefotaxime, ceftriaxone, and ampicillin) plus respiratory fluoroquinolone. 
*Risk factors for Pseudomonas infection: An antipneumococcal, antipseudomonal, β-lactam plus either 
ciprofloxacin or levofloxacin or plus aminoglycoside and azithromycin or plus an aminoglycoside and an 
antipneumococcal fluoroquinolone. 
*Risk factors for MRSA infection: Vancomycin or linezolid 
Abbreviations: Intensive care unit (ICU); drug resistant S pneumoniae (DRSP); methicillin resistant S aureus (MRSA) 
 
